Immatics (NASDAQ:IMTXW) Sees Significant Decline in Short Interest

Immatics (NASDAQ:IMTXW) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 58,900 shares, a drop of 21.9% from the March 15th total of 75,400 shares. Based on an average daily volume of 26,800 shares, the short-interest ratio is presently 2.2 days.

Immatics Stock Performance

Shares of IMTXW stock traded down $0.01 on Monday, hitting $0.01. The company had a trading volume of 700 shares, compared to its average volume of 24,436. Immatics has a twelve month low of $0.01 and a twelve month high of $4.00. The company has a 50-day moving average price of $0.02 and a 200-day moving average price of $0.34.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.